Skip to main content

Profile hero

Profile details

About Dr. Philipp Dohnke

Philipp is a member of our intellectual property and information technology team.

Since joining the firm, he has worked across many industries with a particular focus on life science and technologies. Philipp has broad expertise in complex, high-profile transactions, including large carve-out and asset deal projects. In addition, Philipp is experienced in drafting and negotiating complex commercial contracts.

He speaks German and English.

Recent work

  • Grünenthal on its €500m acquisition of testosterone business ("Nebido") from Bayer
  • Special Olympics World Games Berlin 2023 Organisationskomitee gGmbH on the World Games and the National Games in advance, both taking place in Berlin on contractual and intellectual property related matters (pro bono)
  • International Chemical Investors Group (ICIG) on their sale of CordenPharma (leading global CDMO (contract development & manufacturing organization)) to European private equity firm Astorg
  • Apax and Warburg Pincus on their €5,1bn acquisition of T-Mobile Netherlands
  • Osram on the cave-out and sale of its Digital Systems business in North America to Acuity
  • Thermo Fisher on its €725m acquisition of the viral vector manufacturing business of Novasep (Belgium)
  • AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals
  • Charterhouse / Serb on the $800m acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific Corporation
  • Novartis on its $5.2bn acquisition of pharmaceutical product Xiidra from Takeda/Shire
  • Merck on its €3.4bn carve-out und sale of its consumer health business to Procter & Gamble
  • Boehringer Ingelheim on its €18bn business swap with Sanofi (Consumer Healthcare against Animal Health)
  • Boehringer Ingelheim on its sale of rights in the pharmaceutical product Buscopan in Brazil to Hypera
  • AstraZeneca / MedImmune on the acquisition of Definiens AG
  • BioNTech on license deals and other collaborations in the field of mRNA products / individualized medicines (including with Pfizer, Genentech, Sanofi, Eli Lilly, Bayer Animal Health and Genmab)
  • Advent International on the $1.9bn acquisition of Sanofi's generics business (Zentiva) and on the add-on acquisition of Alvogen's CEE business
  • Bridgepoint on the acquisition of Pharmazell (manufacturer of active pharmaceutical ingredients)
  • BC Partners on the €2.6bn acquisition of CeramTec
  • BC Partners on the acquisition of a majority stake in the Greek generics company Pharmathen
  • Charterhouse / Cooper on the acquisition of a consumer health product portfolio from Sanofi
  • Charterhouse / Serb on the acquisition of rights in a pharmaceutical product from a US biotech company
  • CVC on the acquisition of a 50% stake in the pharmaceutical excipient manufacturer DFE Pharma from Fonterra (Joint Venture with FrieslandCampina)
  • Qatar Investment Authority on an investment in the German biotech company CureVac
  • Airbus on a joint venture with Bombardier regarding the aircraft program "C Series" (now "A220") and on the subsequent exit of Bombardier from the joint venture
  • ABB on the carve-out and sale of its cable business to NKT
  • Cinven/Hotelbeds on the acquisition of the Global Travel Distribution business from Kuoni
  • Continental on the carve-out of its powertrain business ("Vitesco Technologies")
  • Deutsche Bank on the carve-out and listing of its Asset Management business ("DWS")
  • H.I.G. on the carve-out and acquisition of the European polyutherane "system house" business from Covestro
  • Hellman & Friedman on its €2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck



  • Bucerius Law School, Hamburg, Germany, and Université de Paris I (Panthéon-Sorbonne), France (law)
  • Bucerius Law School, Hamburg, Germany (doctorate in law)
  • Traineeship (Referendariat) at the Higher Regional Court of Hamburg, Germany

Professional memberships

  • German Association for the Protection of Intellectual Property


  • Philipp Dohnke, 2013 Vorfeldschutz im Immaterialgüterrecht